Inactive Instrument

News VIVUS, Inc.

Equities

VVUSQ

US9285513084

Pharmaceuticals

All News

Jan. 26	VIVUS LLC Announces the Results of a Randomized Trial Evaluating the Effect of QSYMIA	CI
Jan. 07	VIVUS Introduces Lower Pricing on QSYMIA at Costco Locations Across Hawaii	CI
25-09-04	VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome	CI
25-05-27	VIVUS Announces Qsymia Now Available at Costco Pharmacies Nationwide	CI
25-04-14	VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma	CI
25-03-10	VIVUS Launches QSYMIA in the United Arab Emirates	CI
24-10-23	VIVUS Announces Label Update for QSYMIA	CI
24-05-30	Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma	CI
24-04-22	VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	CI
23-11-28	VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	CI
23-01-10	VIVUS, Inc. Promotes Santosh T. Varghese to President VIVUS Global Pharmaceutical Development	CI
22-07-20	FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	CI
20-12-14	VIVUS : Receives Court Approval of Joint Chapter 11 Plan of Reorganization	AQ
20-12-10	VIVUS, Inc. Emerged from Bankruptcy	CI
20-12-10	Revised Second Amended Reorganization Plan & Disclosure Statement Approved for VIVUS, Inc.	CI
20-11-16	First Motion for Exclusivity Period Extension Approved For VIVUS, Inc.	CI
20-11-16	VIVUS : Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date	AQ
20-11-16	VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-11-10	Second Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	CI
20-11-03	First Motion for Exclusivity Period Extension Filed by VIVUS, Inc.	CI
20-10-20	Motion for Asset Sale Filed by VIVUS, Inc.	CI
20-08-18	First Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	CI
20-07-13	VIVUS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure (form 8-K)	AQ
20-07-10	VIVUS, Inc.(NasdaqGS:VVUS) dropped from S&P TMI Index	CI
20-07-10	Motion for Joint Administration Approved for VIVUS, Inc.	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News VIVUS, Inc.

Equities

VVUSQ

US9285513084

Pharmaceuticals

All News

Filters